On August 31, 2026, JPMorgan Chase & Co. sold 1.25 million shares of InSilico Medicine Cayman TopCo (03696) at an average of HKD 43.5738 per share, involving about HKD 54.69 million.
Prior to the disposal, JPMorgan Chase & Co.'s long position in InSilico Medicine Cayman TopCo was 35.27 million shares, representing 6.05%; following the disposal, the holding changed to 34.01 million shares, with the long position ratio falling to 5.83%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.